Alzheimer's disease: What you need to know
Alzheimer's disease has a devastating impact on every life it touches and the problem continues to get worse as much of the U.S. population ages. The Alzheimer's Association estimates that the costs of the disease on the healthcare system could reach an astronomical $1.1 trillion by 2050, making effective treatments even more necessary.
Yet, the damaging neurological condition has no disease modifying treatments available and has been notoriously hard for the industry to development drugs for. The development pipeline is littered with failure after high-profile, late-stage failure. The low success rate and the high cost of development has limited the number of companies that are both willing and able to continue working in the field, but those that remain have stayed unwaveringly optimistic.
BioPharma Dive explores the science and business shaping the disease.
The unmet need presented by the ever-growing patient population coupled with better science has the Alzheimer's disease pipeline filling up. Read More >>
Almost all Alzheimer’s drugs have failed. But pharma continues to invest millions in hopes of finding a hit, motivated by market opportunity and armed with lessons learned. Read More >>
Genentech's Tom Zioncheck sat down with BioPharma Dive to talk about the big biotech's work in Alzheimer's disease. Read More >>
A growing knowledge of the science behind the disease is allowing researchers to better test potential therapies. Read More >>
As investors eagerly await data on Biogen's aducanumab, BioPharma Dive revisits a therapeutic field littered with failures. Read More >>
Follow Lisa LaMotta on Twitter